Overview

• A Nature Mental Health paper reported that a single ibogaine-magnesium treatment led to average symptom reductions of 88% in PTSD, 87% in depression and 81% in anxiety one month after therapy.
• EEG and MRI analyses linked veterans’ cognitive gains to increased theta wave activity associated with neuroplasticity and decreased cortical complexity tied to reduced stress responses.
• Participants’ functional disability scores on the WHO Disability Assessment Scale fell from levels indicating moderate impairment to near-normal functioning within four weeks.
• The protocol incorporated cardiac-protection measures and produced no serious adverse events or heart complications, with only transient headaches and nausea reported.
• Texas’ $50 million initiative will match private investments to underwrite larger-scale clinical trials aimed at securing FDA approval for ibogaine treatment in traumatic brain injury.